• Simpson JR, Gaspar LE, Aref AM, Imperato JP, Marcus KJ, Rogers CL, Suh JH, Videtic GM, Wolfson AH, McDermott MW, Rogers L, Expert Panel on Radiation Oncology-Brain Metastases. Follow-up and retreatment of brain metastases. [online publication]. Reston (VA): American College of Radiology (ACR); 2006. 11 p. [23 references]

This is the current release of the guideline.

This guideline updates a previous version: Simpson JR, Mendenhall WM, Schupak KD, Larson D, Bloomer WD, Buckley JA, Gaspar LE, Gibbs FA, Lewin AA, Loeffler JS, Malcolm AW, Schneider JF, Shaw EG, Wharam MD Jr, Gutin PH, Rogers L, Leibel S. Follow-up and retreatment of brain metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000 Jun;215(Suppl):1129-35.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

ACR Appropriateness Criteria®

Clinical Condition: Follow-up and Retreatment of Brain Metastasis

Variant 1: 70-year-old man with non-small-cell lung cancer s/p lobectomy 3 years ago with a single brain metastasis 1 year ago treated with radiosurgery. Now with new contralateral metastasis in non-dominant temporal lobe measuring 2 cm. KPS is 80.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 2: 60-year-old man with renal cancer history, s/p surgical resection of two cerebellar metastases and postop WBRT (35 Gy in 14 fractions) 18 months ago. Now with new 3 cm left frontal metastasis without edema. KPS is 90. No other signs of recurrence.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 3: 44-year-old woman with metastatic breast cancer and multiple brain metastases 9 months ago, s/p WBRT (3000 cGy in 10 fractions). Now with recurrence of 2 asymptomatic bilateral anterior frontal masses, 1-2 cm in diameter each. KPS is 80.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 4: 49-year-old woman with widely metastatic melanoma, s/p WBRT (3000 cGy in 10 fractions) for multiple metastases 6 months ago. Now with recurrence of one 3.5 cm right parietal metastasis with edema causing weakness. KPS is 70.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 5: 76-year-old woman with a history of colon cancer 6 years ago and a single cerebellar metastasis 1 year ago, treated with WBRT (to 30 Gy in 10 fractions) and posterior fossa boost to 40 Gy. Now with new 2.5 cm right parietal lobe metastasis causing left-sided weakness. Posterior fossa lesion stable. KPS is 80. No other extracranial disease.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 6: 62-year-old woman with recurrent ovarian cancer in the pelvis and metastases to the frontal and temporal lobes 1 year ago, treated with craniotomy for the larger frontal tumor and postoperative radiosurgery to both intracranial sites. Now with a new lateral cerebellar metastasis 2.8 cm in maximum diameter. Systemic disease is present and progressive over past 3 months. KPS is 60.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 7: 37-year-old man with non-small-cell lung cancer and synchronous bilateral frontal metastases 8 months ago treated with radiosurgery only. Now with a new 4 cm parietal lobe metastasis affecting motor strength. There is progressive systemic disease. KPS is 70.

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 8: Follow-up after treatment of brain metastases. (Assuming in prior variants that treatment was carried out as planned, what is the frequency and modality of imaging in combination with a physical exam?).

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Summary of Literature Review

Retreatment for brain metastases may be required following a variety of initial treatments such as whole brain irradiation, surgery, radiosurgery, chemotherapy, and combinations of these. The choice of recurrent treatment modality will depend on the size, number, timing, and location of the recurrent metastases as well as the patient's performance status and extent of extra central nervous system (CNS) disease beyond the central nervous system. There appears to be an increasing number of patients who have received only surgery or radiosurgery as their initial management of brain metastases. This trend is likely driven by the increasing availability of stereotactic radiosurgery, improvements in neuroimaging and surgical techniques, and patient desires for quality of life choices in health care.

Whole brain irradiation (WBRT) may be the least attractive option for retreatment after initial WBRT, although some authors dispute this. Less response is usually seen than with the first course, it is usually transient, and patients' morbidity is high if they survive long enough. Panel members consistently deemed whole brain reirradiation a less appropriate choice than the other alternatives.

Radiosurgery for recurrent brain metastases is a viable option if size and number permit. One study reported 1 and 2 years local control rates of 91% and 84% respectively, in 54 consecutive patients with radiosurgery for reirradiation of brain metastases following initial WBRT. Radiographic responses have been well documented for salvage radiosurgery, although evidence for a survival benefit is not strong. This modality is increasingly available at many centers.

Chemotherapy has occasionally been a successful strategy for chemosensitive tumors, whereas repeat surgery may be useful depending on patient condition.

Increasing evidence shows that some chemotherapy and biological treatments may be effective in brain metastases.

Follow-up of Brain Metastases

The best method of follow-up of brain metastases after treatment is complicated by the lack of reliable early indicators of response or progression. One study reported on the imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors, finding that 22% of 35 metastatic tumors appeared larger on magnetic resonance imaging (MRI) at a mean of 10 weeks after radiosurgery. Eleven had fluorodeoxyglucose positron emission tomography (FDG-PET) performed for enlarging lesions -- eight showed increased brain activity, while three showed decreased activity. Of the eight, however, six were incorrectly predicted based on the patient's subsequent course (alive, mean follow-up of 27 months). The authors suggested that further evaluation of Thallium-201 and hexamethylpropyleneamine oxime (HMPAO), single-photon- emission computed tomography (SPECT) or magnetic resonance spectroscopy (MRS) was warranted. Dynamic susceptibility-weighted contrast-enhanced MRI has recently been suggested to improve prediction of tumor response after treatment for brain metastases and primary brain tumor.

The most appropriate frequency and type of follow-up after retreatment of a patient with brain metastases is a matter of debate. Given its wide availability in this country and superior sensitivity over computed tomography (CT), MRI is the preferred imaging modality. It is an expensive option, however, and its frequency of use should depend on the likelihood of obtaining useful information, not otherwise available, which could be acted upon for the patient's benefit.

A not uncommon problem after the treatment of brain metastases is the differentiation between tumor recurrence and radiation-induced scar tissue or necrosis. This is a particularly vexing problem in the patient who is asymptomatic and has a high performance status. F-18 deoxyglucose and methyl methionine PET scanning has been studied most and advocated for this purpose. When brain recurrence is confirmed, surgery and particularly radiosurgery may be useful in extending survival.

Summary

The issue of postirradiation management and retreatment thus revolves around three concerns. One is the need to assess the effects of and deal with any sequelae of treatment. Second is appropriate surveillance so that further treatment can be administered prior to symptoms when the patient may best tolerate additional treatment. The third is the goal of detecting recurrences when their size does not preclude the use of radiosurgery, arguably the most effective emerging option.

Abbreviations

• CT, computed tomography
• FDG-PET, fluorodeoxyglucose positron emission tomography
• KPS, Karnofsky Performance Status
• MRI, magnetic resonance imaging
• s/p, status-post
• SRS, stereotactic radiosurgery
• WBRT, whole brain radiotherapy

Algorithms were not developed from criteria guidelines.

The recommendations are based on analysis of the current literature and expert panel consensus.

• Simpson JR, Gaspar LE, Aref AM, Imperato JP, Marcus KJ, Rogers CL, Suh JH, Videtic GM, Wolfson AH, McDermott MW, Rogers L, Expert Panel on Radiation Oncology-Brain Metastases. Follow-up and retreatment of brain metastases. [online publication]. Reston (VA): American College of Radiology (ACR); 2006. 11 p. [23 references]

Not applicable: The guideline was not adapted from another source.

1999 (revised 2006)

American College of Radiology - Medical Specialty Society

The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria®

Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology-Brain Metastases

Panel Members: Joseph R. Simpson, MD; Laurie E. Gaspar, MD, MBA; Amr M. Aref, MD; Joseph P. Imperato, MD; Karen J. Marcus, MD; C. Leland Rogers, MD; John H. Suh, MD; Gregory M. Videtic, MD; Aaron H. Wolfson, MD; Michael W. McDermott, MD; Lisa Rogers, DO

Not stated

This is the current release of the guideline.

This guideline updates a previous version: Simpson JR, Mendenhall WM, Schupak KD, Larson D, Bloomer WD, Buckley JA, Gaspar LE, Gibbs FA, Lewin AA, Loeffler JS, Malcolm AW, Schneider JF, Shaw EG, Wharam MD Jr, Gutin PH, Rogers L, Leibel S. Follow-up and retreatment of brain metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000 Jun;215(Suppl):1129-35.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

None available

This summary was completed by ECRI on January 30, 2001. The information was verified by the guideline developer as of February 20, 2001. This NGC summary was updated by ECRI Institute on May 16, 2007.